EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.

Vendrell, Julie A; Quantin, Xavier; Aussel, Audrey; Solassol, Isabelle; Serre, Isabelle; Solassol, Jérôme

Vendrell, Julie A; Quantin, Xavier; Aussel, Audrey; Solassol, Isabelle; Serre, Isabelle; Solassol, Jérôme.

Afiliação

Vendrell JA; CHU Montpellier, Department of Pathology and Onco-biology, Univ Montpellier, Montpellier, France.
Quantin X; IRCM, INSERM, Univ Montpellier, ICM, Montpellier, France.
Aussel A; CHU Montpellier, Department of Pathology and Onco-biology, Univ Montpellier, Montpellier, France.
Solassol I; IURT, ICM, Montpellier, France.
Serre I; CHU Montpellier, Department of Pathology and Onco-biology, Univ Montpellier, Montpellier, France.
Solassol J; CHU Montpellier, Department of Pathology and Onco-biology, Univ Montpellier, Montpellier, France.

Transl Lung Cancer Res ; 10(11): 4084-4094, 2021 Nov.

Article em En | MEDLINE | ID: mdl-35004240

Palavras-chave

EGFR-TKI resistance; circulating tumor DNA; clinical outcome; lung cancer; osimertinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Transl Lung Cancer Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google